China Approves Groundbreaking Wound Treatment Drug for Sino Biopharma’s Subsidiary – First-of-Its-Kind Approval in [Year]
China’s National Medical Products Administration (NMPA) has approved the commercialization of a first-in-class wound-healing drug for diabetic foot ulcers, marking a significant milestone in treating chronic non-healing wounds. Developed by Sino Biopharmaceutical’s subsidiary, the therapy—identified as recombinant human platelet-derived growth factor-BB (rhPDGF-BB)—is now available for patients with diabetic foot ulcers that have failed conventional treatments, … Read more